Mai Capital Management Albireo Pharma, Inc. Transaction History

Mai Capital Management

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$18.01 - $23.78 $2.55 Million - $3.36 Million	-141,469 Reduced 34.77%	265,364 $5.73 Million
Q3 2022 Nov 15, 2022	BUY	$16.32 - $26.37 $2.79 Million - $4.5 Million	170,686 Added 72.28%	406,833 $7.88 Million
Q2 2022 Jul 19, 2022	BUY	$18.54 - $37.29 $695,175 - $1.4 Million	37,496 Added 18.88%	236,147 $4.69 Million
Q1 2022 May 10, 2022	BUY	$23.94 - $33.74 $1.41 Million - $1.99 Million	59,100 Added 42.35%	198,651 $5.93 Million
Q4 2021 Feb 11, 2022	BUY	$21.19 - $31.29 $2.72 Million - $4.02 Million	128,321 Added 1142.66%	139,551 $3.25 Million

Q3 2021 Nov 12, 2021	SELL	$27.36 - $35.98 $38,304 - $50,371	-1,400 Reduced 11.08%	11,230 $350,000
Q2 2021 Jul 19, 2021	SELL	$28.9 - $36.87 $233,743 - $298,204	-8,088 Reduced 39.04%	12,630 $444,000
Q1 2021 May 10, 2021	SELL	$32.03 - $42.85 $35,297 - $47,220	-1,102 Reduced 5.05%	20,718 $730,000
Q4 2020 Feb 16, 2021	BUY	$31.56 - $42.16 $176,231 - $235,421	5,584 Added 34.39%	21,820 $818,000
Q3 2020 Oct 26, 2020	SELL	$23.19 - $41.61 $10,296 - $18,474	-444 Reduced 2.66%	16,236 $542,000
Q2 2020 Jul 27, 2020	BUY	$14.82 - $29.92 $75,582 - $152,592	5,100 Added 44.04%	16,680 $442,000
Q1 2020 Apr 16, 2020	SELL	$11.67 - $27.23 $9,919 - $23,145	-850 Reduced 6.84%	11,580 $190,000
Q4 2019 Feb 03, 2020	BUY	$16.92 - $28.96 $210,315 - $359,972	12,430 New	12,430 $316,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

Stay updated on Mai Capital Management with notifications on news.